Phase I/II – Other

632 trials 274 recruiting

Filter these 632 trials by condition, country, sponsor and more.

Open in Search →

CO43923 Master Protocol: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients with Multiple Myeloma CO43923 Substud… Recruiting

2023-504484-16-00 Multiple Myeloma (MM) 2022-11-18
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Che… Recruiting

2023-504264-41-00 CD20 positive B-Cell Non-Hodgkin Lymphoma (NHL) 2022-11-04
A phase 1b/2, multicenter, adaptive, double-blind, randomized, placebo-controlled study to assess the safety, tolerability, immunogenicity, … Recruiting

2022-500069-29-00 Alzheimer's disease 2022-11-02
Phase I/II dose escalation trial of radiodynamic therapy (RDT) with 5-Aminolevulinic acid in patients with first recurrence of glioblastoma Recruiting

2024-517651-12-00 recurrent glioblastoma 2022-10-28
Administration of the BCL-2 antagonist, venetoclax, to promote apoptosis of HIV-infected cells and reduce the size of the HIV reservoir: An … Recruiting

2024-518873-32-00 HIV-1 disease 2022-10-28
A long-term monitoring study of patients suffering from a malignant neoplasm of the central nervous system previously treated with hematopoi… Recruiting

2024-516211-25-00 Glioblastoma multiforme (GBM) 2022-10-27
Study to determine the dose and safety of asciminib in pediatric patients with chronic myeloid leukemia. Recruiting

2023-508129-28-00 Pediatric patients with Philadelphia chromosome positiv 2022-09-28
SPRING Rollover Recruiting

2022-500041-24-00 Lung cancer (non-small cell lung cancer) 2022-09-27
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or … Recruiting

2023-506517-22-00 Advanced or Metastatic Colorectal Cancer 2022-08-31
This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin… Recruiting

2023-505347-38-00 B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lym 2022-06-13
A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to … Recruiting

2024-515354-24-00 Low risk myelodysplastic syndrom without RS having fail 2022-05-18
Study evaluating the clinical impact of HDM201 + Pazopanib in patients with P53 wild-type advanced/ metastatic soft tissue sarcomas. Recruiting

2024-510706-86-00 Advanced/ metastatic soft tissue sarcomas 2022-05-16
Brigatinib in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors (Briga-PED) Recruiting

2024-513412-10-00 Anaplastic Large Cell Lymphoma (ALCL) 2022-05-11
Study of BGB-11417 in Patients with Myeloid Malignancies Recruiting

2023-508881-14-00 Myeloid malignancies (acute myeloid leukemia (AML), mye 2022-03-21
Intrathecal application of PD-1 antibody in metastatic solid tumors with leptomeningeal disease Recruiting

2024-514068-14-00 leptomeningeal disease 2021-10-12
Isatuximab in combination with novel agents in RRMM – Master protocol and control arm Recruiting

2024-514988-25-00 Cancer 2021-03-31
Isatuximab in combination with SAR445761 (belumosudil) and dexamethasone in relapsed or refractory multiple myeloma Recruiting

2024-514992-16-00 Cancer 2021-03-31
Isatuximab in combination with evorpacept and dexamethasone in RRMM Recruiting

2024-514993-38-00 Cancer 2021-03-31
Neoadjuvant Immunotherapy with Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) foll… Recruiting

2024-518804-32-00 Non-Small Cell Lung Cancer (NSCLC) 2021-02-16
RElapse in previously irradiated Prostate bed : a phase I/II study of stereotactic Ablative reIRradiation potentiated by Metformine (REPAIR … Recruiting

2022-502642-27-00 RElapse in previously irradiated Prostate bed 2020-11-26
FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Recruiting

2024-510579-40-00 Rhabdoyosarcoma 2020-10-07
A study of Trastuzumab Deruxtecan to assess its safety, tolerability, immune response, and inhibition of tumor activity when given alone or … Recruiting

2023-504888-16-00 Patients with Human Epidermal Growth Factor Receptor 2 2020-10-05
Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia (MOSAIC) Recruiting

2024-514014-13-00 female and male adult patients with acute myeloid leuke 2020-09-02
Clinical trial to evaluate safety and effectiveness of APL-101 for the treatment of advanced MET expressing solid tumors, including Non-Smal… Recruiting

2024-514542-37-00 Select advanced solid tumors and Non-Small Cell Lung Ca 2020-08-13